Welcome to Arctom, sign up to enjoy up to 20% OFF
- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 356547-88-1] Belimumab
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-P9952 |
| Brand: | MCE |
| CAS: | 356547-88-1 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Belimumab] |
For research use only. We do not sell to patients.
Summary
Belimumab (LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF) . Belimumab can be used for systemic lupus erythematosus (SLE) research [1] .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03207958 | Washington University School of Medicine|GlaxoSmithKline|American Cancer Society, Inc. |
Graft Vs Host Disease|Graft-versus-host-disease
|
May 16, 2018 | Phase 1 |
| NCT01484496 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline |
Systemic Lupus Erythematosus
|
November 16, 2011 | Phase 3 |
| NCT00583362 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline |
Systemic Lupus Erythematosus
|
May 4, 2005 | Phase 2 |
| NCT00712933 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline |
Systemic Lupus Erythematosus
|
May 30, 2008 | Phase 3 |
| NCT05588830 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Lupus Nephritis|Belimumab|Telitacicept
|
October 20, 2022 | |
| NCT01762852 | GlaxoSmithKline |
Glomerulonephritis, Membranous
|
April 2013 | Phase 2 |
| NCT05069051 | University Hospital Tuebingen|GlaxoSmithKline |
Chronic Lymphoid Leukemia in Relapse
|
January 19, 2022 | Phase 2 |
| NCT04179032 | GlaxoSmithKline |
Systemic Lupus Erythematosus
|
November 28, 2019 | Phase 2 |
| NCT05154734 | Tianjin Medical University General Hospital |
NMO Spectrum Disorder
|
October 30, 2021 | Phase 1|Phase 2 |
| NCT00732940 | Human Genome Sciences Inc.|GlaxoSmithKline |
Systemic Lupus Erythematosus
|
October 2008 | Phase 2 |
| NCT01610492 | GlaxoSmithKline |
Glomerulonephritis, Membranous
|
July 1, 2012 | Phase 2 |
| NCT03591380 | University of Wisconsin, Madison|GlaxoSmithKline|American College of Surgeons |
Kidney Transplantation
|
May 14, 2019 | Phase 2 |
| NCT05604742 | xuna|Nanfang Hospital of Southern Medical University |
cGVHD
|
January 1, 2022 | Phase 1|Phase 2 |
| NCT03747159 | Leiden University Medical Center|Dutch Kidney Foundation|GlaxoSmithKline |
Lupus Erythematosus, Systemic
|
October 1, 2018 | Phase 3 |
| NCT03312907 | GlaxoSmithKline |
Systemic Lupus Erythematosus
|
March 1, 2018 | Phase 3 |
| NCT02347891 | Northwell Health|GlaxoSmithKline |
Myositis
|
January 2015 | Phase 2|Phase 3 |
| NCT05338190 | Assistance Publique - Hôpitaux de Paris|GlaxoSmithKline |
Primary Immune Thrombocytopenia (ITP)
|
June 1, 2022 | Phase 3 |
| NCT02270970 | Oklahoma Medical Research Foundation|GlaxoSmithKline |
Systemic Lupus Erythematosus
|
October 2014 | Phase 4 |
| NCT01583530 | Human Genome Sciences Inc.|GlaxoSmithKline |
Healthy
|
February 2011 | Phase 1 |
| NCT02880852 | GlaxoSmithKline |
Systemic Lupus Erythematosus
|
January 23, 2017 | Phase 1 |
| NCT04660565 | Peking Union Medical College Hospital |
IgG4-related Disease
|
January 2021 | Phase 4 |
| NCT02119156 | GlaxoSmithKline |
Systemic Lupus Erythematosus
|
May 13, 2014 | Phase 3 |
| NCT01480596 | GlaxoSmithKline |
Myasthaenia Gravis
|
April 2013 | Phase 2 |
| NCT00931086 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline |
Rheumatoid Arthritis
|
April 2009 | |
| NCT04570306 | Biomedical Research Foundation, Academy of Athens |
Systemic Lupus Erythematosus
|
December 31, 2020 | |
| NCT00410384 | Human Genome Sciences Inc.|GlaxoSmithKline |
Systemic Lupus Erythematosus
|
December 2006 | Phase 3 |
| NCT03949855 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|GlaxoSmithKline|PPD|Rho Federal Systems Division, Inc. |
Membranous Nephropathy|Nephrotic Syndrome
|
December 18, 2019 | Phase 2 |
| NCT01597622 | GlaxoSmithKline|Human Genome Sciences Inc. |
Systemic Lupus Erythematosus
|
June 11, 2012 | Phase 3 |
| NCT04136145 | GlaxoSmithKline |
Systemic Lupus Erythematosus
|
October 28, 2019 | Phase 1 |
| NCT01536379 | GlaxoSmithKline |
Transplantation, Organ
|
September 2013 | Phase 2 |
| NCT02631538 | GlaxoSmithKline |
Sjogren´s Syndrome
|
February 17, 2016 | Phase 2 |
| NCT04447053 | National University Hospital, Singapore|GlaxoSmithKline |
Systemic Lupus Erythematosus
|
November 8, 2021 | Phase 4 |
| NCT00071812 | Human Genome Sciences Inc. |
Arthritis, Rheumatoid
|
December 2003 | Phase 2 |
| NCT02124798 | GlaxoSmithKline |
Systemic Lupus Erythematosus
|
May 20, 2014 | Phase 2 |
| NCT04893161 | First Affiliated Hospital Xi´an Jiaotong University |
Systemic Lupus Erythematosus
|
January 1, 2023 | Phase 4 |
| NCT00583557 | Human Genome Sciences Inc. |
Rheumatoid Arthritis
|
January 2005 | Phase 2 |
| NCT02260934 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Lupus Nephritis
|
July 9, 2015 | Phase 2 |
| NCT04097561 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Idiopathic CD4 Lymphopenia
|
January 13, 2020 | Phase 1 |
| NCT03967925 | Rachel Jones|GlaxoSmithKline|Medical Research Council|Imperial College London|University College, London|Newcastle University|University of Glasgow|University of Cambridge|Cambridge University Hospitals NHS Foundation Trust |
ANCA Associated Vasculitis|Granulomatosis With Polyangiitis
|
February 1, 2019 | Phase 2 |
| NCT05020782 | University of Turin, Italy |
Antiphospholipid Syndrome
|
June 1, 2022 | Phase 2|Phase 3 |
| NCT00424476 | Human Genome Sciences Inc.|GlaxoSmithKline |
Systemic Lupus Erythematosus
|
May 2007 | Phase 3 |
| NCT05262686 | Peking University People´s Hospital |
Systemic Lupus Erythematosus
|
April 1, 2022 | Phase 3 |
| NCT01705977 | GlaxoSmithKline |
Systemic Lupus Erythematosus
|
November 27, 2012 | Phase 4 |
| NCT04767698 | Johns Hopkins University|GlaxoSmithKline |
Multiple Sclerosis
|
October 1, 2021 | Phase 2 |
| NCT01532310 | GlaxoSmithKline|PPD |
Systemic Lupus Erythematosus
|
July 16, 2012 | |
| NCT01142011 | Cancer Trials Australia|Human Genome Sciences Inc. |
Symptomatic Waldenstroms Macroglobulinaemia
|
November 2009 | Phase 2 |
| NCT01597492 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline |
Systemic Lupus Erythematosus
|
May 31, 2012 | Phase 4 |
| NCT01663623 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline |
Vasculitis
|
March 20, 2013 | Phase 3 |
| NCT03244059 | University of Alabama at Birmingham|GlaxoSmithKline |
Chronic Obstructive Pulmonary Disease|Emphysema
|
August 9, 2018 | Phase 2 |
| NCT01914770 | GlaxoSmithKline|Human Genome Sciences Inc. |
Systemic Lupus Erythematosus
|
July 2009 | |
| NCT04629144 | Assistance Publique - Hôpitaux de Paris |
Vasculitis|Cryoglobulinemia
|
March 1, 2021 | Phase 2 |
| NCT00071487 | Human Genome Sciences Inc. |
Lupus Erythematosus, Systemic
|
October 2003 | Phase 2 |
| NCT01639339 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline |
Lupus Nephritis
|
July 12, 2012 | Phase 3 |
| NCT00724867 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline |
Systemic Lupus Erythematosus
|
August 2008 | Phase 3 |
| NCT01345253 | GlaxoSmithKline|Human Genome Sciences Inc. |
Systemic Lupus Erythematosus
|
May 23, 2011 | Phase 3 |
| NCT01649765 | GlaxoSmithKline|Human Genome Sciences Inc., a GSK Company |
Systemic Lupus Erythematosus
|
September 7, 2012 | Phase 2 |
| NCT01440361 | GlaxoSmithKline |
Purpura, Thrombocytopaenic, Idiopathic
|
March 2013 | Phase 2 |
| NCT01670565 | Hospital for Special Surgery, New York|Human Genome Sciences Inc. |
Systemic Sclerosis
|
August 2012 | Phase 2 |
| NCT00657007 | Human Genome Sciences Inc. |
Systemic Lupus Erythematosus
|
February 2002 | Phase 1 |
| NCT04515719 | RenJi Hospital |
Systemic Lupus Erythematosus
|
March 19, 2021 | Phase 4 |
| NCT01632241 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline |
Systemic Lupus Erythematosus
|
February 19, 2013 | Phase 4 |
| NCT01160666 | Assistance Publique - Hôpitaux de Paris|Human Genome Sciences Inc. |
Sjögren´s Syndrome
|
March 2010 | Phase 2 |
| NCT01858792 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline |
Lupus Erythematosus, Discoid
|
May 2011 | |
| NCT03844061 | Hospital for Special Surgery, New York|GlaxoSmithKline |
Systemic Sclerosis
|
July 29, 2019 | Phase 2 |
| NCT02500251 | E. Steve Woodle|GlaxoSmithKline|University of Cincinnati |
Renal Transplant Rejection
|
June 2015 | Phase 1|Phase 2 |
| NCT04908865 | GlaxoSmithKline |
Systemic Lupus Erythematosus
|
October 21, 2021 | Phase 4 |
| NCT01025193 | University of Pennsylvania|Human Genome Sciences Inc. |
Desensitization
|
February 2010 | Phase 2 |
| NCT02284984 | Leiden University Medical Center|Dutch Kidney Foundation|ZonMw: The Netherlands Organisation for Health Research and Development |
Lupus Erythematosus, Systemic
|
March 2014 | Phase 2 |
| NCT05585671 | RenJi Hospital |
Whether Belimumab Could Reduce 2-year Risk of New-onset Lupus Nephritis
|
June 1, 2023 | |
| NCT04956484 | Peking Union Medical College Hospital |
Lupus Erythematosus, Systemic
|
September 1, 2021 | Phase 4 |
| NCT03125486 | GlaxoSmithKline |
Systemic Lupus Erythematosus
|
||
| NCT01894360 | GlaxoSmithKline |
Systemic Lupus Erythematosus
|
October 14, 2013 | Phase 1 |
| NCT03543839 | Northwell Health|GlaxoSmithKline |
Lupus Erythematosus, Systemic|Lupus Erythematosus
|
September 15, 2020 | Phase 4 |
Appearance
Solid
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Request a Quote
Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.
Information
Customer service
My account
Powered by Arctom
Copyright © 2021 Arctom. All rights reserved.